Souvenaid®: A new approach to management of early Alzheimer's disease

Journal of Nutrition, Health and Aging

Volumn 18, Issue 3, 2014, Pages 291-299

  Ritchie, C W ^a   Bajwa, J ^b   Coleman, G ^c   Hope, K ^d   Jones, R W ^e   Lawton, M ^f   Marven, M ^g   Passmore, P ^h  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Conway Medical Centre ^*  (United Kingdom)

^c Registered Dietitian   (United Kingdom)

^d UNIVERSITY OF STIRLING   (United Kingdom)

^e ROYAL UNITED HOSPITAL   (United Kingdom)

^f Ravenswood Clinic   (United Kingdom)

^g OXFORD HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^h QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Alzheimer's disease; Dietary management; Medical food; Souvenaid ; Synapse

Indexed keywords

CHOLINE; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; PHOSPHOLIPID; SOUVENAID; UNCLASSIFIED DRUG; URIDINE PHOSPHATE; CHOLINESTERASE INHIBITOR; MEMANTINE;

ALZHEIMER DISEASE; DIET SUPPLEMENTATION; FUNCTIONAL FOOD; HUMAN; MEMORY; NERVE DEGENERATION; NEUROPSYCHOLOGICAL TEST; NONHUMAN; NUTRITIONAL DEFICIENCY; PHOSPHOLIPID SYNTHESIS; PRIORITY JOURNAL; REVIEW; SYNAPTIC MEMBRANE; SYNAPTOGENESIS; DIET THERAPY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; EPISODIC MEMORY; EUROPEAN UNION; FEMALE; MALE; PATHOLOGY; PATHOPHYSIOLOGY; PRODROMAL SYMPTOM; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYNAPSE;

ALZHEIMER DISEASE; CHOLINE; CHOLINESTERASE INHIBITORS; DISEASE PROGRESSION; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; EUROPEAN UNION; FEMALE; HUMANS; MALE; MEMANTINE; MEMORY, EPISODIC; PRODROMAL SYMPTOMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYNAPSES; URIDINE MONOPHOSPHATE;

EID: 84899087887     PISSN: 12797707     EISSN: 17604788     Source Type: Journal    
DOI: 10.1007/s12603-013-0411-2     Document Type: Review

References (82)

1. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12:383-388.
2. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-185.
3. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002;298:789-791. (Pubitemid 35231524)
4. Rosenstein LD. Differential diagnosis of the major progressive dementias and depression in middle and late adulthood: a summary of the literature of the early 1990s. Neuropsychol Rev 1998;8:109-167. (Pubitemid 28554535)
5. Sabbagh MN, Cooper K, DeLange J, Stoehr JD, Thind K, Lahti T, Reisberg B, Sue L, Vedders L, Fleming SR, Beach TG. Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD. Curr Alzheimer Res 2010;7:280-286.
6. Zhou L, Chan KH, Chu LW, Kwan JS, Song YQ, Chen LH, Ho PW, Cheng OY, Ho JW, Lam KS. Plasma amyloid-β oligomers level is a biomarfcer for Alzheimer's disease diagnosis. Biochem Biophys Res Commun 2012;423:697-702.
7. Santos AN, Ewers M, Minthon L, Simm A, Silber RE, Blennow K, Prvulovic D, Hansson O, Hampel H. Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. J Alzheimers Dis 2012;29:171-176.
8. Scheff SW, Price DA. Alzheimer's disease-related alterations in synaptic density: neocortex and hippocampus. J Alzheimers Dis 2006;9(3 Suppl):101-115. (Pubitemid 44253303)
9. Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 2006;27:1372-1384. (Pubitemid 44279897)
10. Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 2007;68:1501-1508. (Pubitemid 46685921)
11. Scheff SW, Price DA, Schmitt FA, Scheff MA, Mufson EJ. Synaptic loss in the inferior temporal gyrus in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 2011;24:547-557.
12. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572-580.
13. Terry RD. Alzheimer's disease and the aging brain. J Geriatr Psychiatry Neurol 2006;19:125-128. (Pubitemid 44154851)
14. Ritchie CW, Zhinchin G. Low dose, high dose, or no dose: better prescribing of cholinesterase inhibitors for Alzheimer's disease. Int Psychogeriatr 2013;25:511-515.
15. Sigurdsson EM. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. Curr Alzheimer Res 2009;6:446-450.
16. Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau based immunization strategies. Immunotherapy 2012;4:213-238.
17. Götz J, Ittner A, Ittner LM. Tau-targeted treatment strategies in Alzheimer's disease. Br J Pharmacol 2012;165:1246-1259.
18. Toni N, Teng EM, Bushong EA, Aimone JB, Zhao C, Consiglio A, van Praaq H, Martone ME, Ellisman MH, Gage FH. Synapse formation on neurons born in the adult hippocampus. Nat Neurosci 2007;10:727-734. (Pubitemid 46828514)
19. Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ. Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci USA 1992;89:1671-1675.
20. Pettegrew JW, Panchalingam K, Hamilton RL, McClure RJ. Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 2001;26:771-782. (Pubitemid 32845968)
21. Damoiseaux JS, Prater KE, Miller BL, Greicius MD. Functional connectivity tracks clinical deterioration in Alzheimer's disease. Neurobiol Aging 2012;33:828 e19-e30.
22. Stam CJ, de Haan W, Daffertshofer A, Jones BF, Manshanden I, van Cappellen van Walsum AM, Montez T, Verbunt JP, de Munck JC, van Dijk BW, Berendse HW, Scheltens P. Graph theoretical analysis of magnetoencephalographic functional connectivity in Alzheimer's disease. Brain 2009;132:213-224.
23. Sperling RA, Laviolette PS, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, Marshall G, Hyman BT, Selkoe DJ, Hedden T, Buckner RL, Becker JA, Johnson KA. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009;63:178-188.
24. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-292.
25. Sastry PS. Lipids of nervous tissue: composition and metabolism. Prog Lipid Res 1985;24:69-176.
26. Butterfield DA, Howard B, Yatin S, Koppal T, Drake J, Hensley K, Aksenov M, Aksenova M, Subramaniam R, Varadarajan S, Harris-White ME, Pedigo NW, Carney JM. Elevated oxidative stress in models of normal brain aging and Alzheimer's disease. Life Sci 1999;65:1883-1892. (Pubitemid 29506923)
27. Kennedy EP, Weiss SB. The function of cytidine coenzymes in the biosynthesis of phospholipides. J Biol Chem 1956;222:193-214.
28. Scarmeas N, Stem Y, Tang M-X, Mayeux R, Luchsinger JA. Mediterranean diet and risk for Alzheimer's disease. Ann Neurol 2006;59:912-921. (Pubitemid 43830923)
29. Loef M, Walach H. Fruit, vegetables and prevention of cognitive decline or dementia: a systematic review of cohort studies. J Nutr Health Aging 2012;16:626-630.
30. Gu Y, Nieves JW, Stern Y, Luchsinger JA, Scarmeas N. Food combination and Alzheimer disease risk: a protective diet. Arch Neurol 2010;67:699-706.
31. Igarashi M, Ma K, Gao F, Kim HW, Rapoport SI, Rao JS. Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex. J Alzheimers Dis 2011;24:507-517.
32. Mulder C, Wahlund LO, Teerlink T, Blomberg M, Veerhuis R, van Kamp GJ, Scheltens P, Scheffer PG. Decreased lysophosphatidylcholine/phosphatidyl choline ratio in cerebrospinal fluid in Alzheimer's disease. J Neural Transm 2003;110:949-955. (Pubitemid 36981409)
33. Glasø M, Nordbø G, Diep L, Bøhmer T. Reduced concentrations of several vitamins in normal weight patients with late-onset dementia of the Alzheimer type without vascular disease. J Nutr Health Aging 2004;8:407-413. (Pubitemid 39294654)
34. Scheltens P, Kamphuis PJ, Verhey FR, Olde Rikkert MG, Wurtman RJ, Wilkinson D, Twisk JW, Kurz A. Efficacy of a medical food in mild Alzheimer's disease: a randomized, controlled trial. Alzheimers Dement 2010;6:1-10.
35. Wurtman RJ, Cansev M, Sakamoto T, Ulus IH. Use of phosphatide precursors to promote synaptogenesis. Annu Rev Nutr 2009;29:59-87.
36. Wurtman RJ, Ulus IH, Cansev M, Watkins CJ, Wang L, Marzloff G. Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally. Brain Res 2006;1088:83-92. (Pubitemid 43729416)
37. Cansev M, Wurtman RJ. Chronic administration of docosahexaenoic acid or eicosapentaenoic acid, but not arachidonic acid, alone or in combination with uridine, increases brain phosphatide and synaptic protein levels in gerbils. Neuroscience 2007;148:421-431. (Pubitemid 47364815)
38. Sakamoto T, Cansev M, Wurtman RJ. Oral supplementation with docosahexaenoic acid and uridine-5′-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res 2007;1182:50-59. (Pubitemid 350086992)
39. Wang CS, Lee RK. Choline plus cytidine stimulate phospholipid production, and the expression and secretion of amyloid precursor protein in rat PC12 cells. Neurosci Lett 2000;283:25-28. (Pubitemid 30145488)
40. Darios F, Davletov B. Omega-3 and omega-6 fatty acids stimulate cell membrane expansion by acting on syntaxin 3. Nature 2006;440:813-817.
41. Pooler AM, Guez DH, Benedictus R, Wurtman RJ. Uridine enhances neurite outgrowth in nerve growth factor-differentiated PC12 [corrected]. Neuroscience 2005;134:207-214. (Pubitemid 40943647)
42. Ina A, Kamei Y. Vitamin B(12), a chlorophyll-related analog to pheophytin a from marine brown algae, promotes neurite outgrowth and stimulates differentiation in PC12 cells. Cytotechnology 2006;52:181-187. (Pubitemid 46686120)
43. Calderon F, Kim HY. Docosahexaenoic acid promotes neurite growth in hippocampal neurons. J Neurochem 2004;90:979-988. (Pubitemid 39099980)
44. Wang L, Albrecht MA, Wurtman RJ. Dietary supplementation with uridine-5′-monophosphate (UMP), a membrane phosphatide precursor, increases acetylcholine level and release in striatum of aged rat. Brain Res 2007;1133:42-48. (Pubitemid 46123254)
45. Farkas E, de Wilde MC, Kiliaan AJ, Meijer J, Keijser JN, Luiten PG. Dietary long chain PUFAs differentially affect hippocampal muscarinic 1 and serotonergic 1A receptors in experimental cerebral hypoperfusion. Brain Res 2002;954:32-41. (Pubitemid 35230003)
46. Savelkoul PJ, Janickova H, Kuipers AA, Hageman RJ, Kamphuis PJ, Dolezal V, Broersen LM. A specific multi-nutrient formulation enhances M1 muscarinic acetylcholine receptor responses in vitro. J Neurochem 2012;120:631-640.
47. De Bruin NM, Kiliaan AJ, De Wilde MC, Broersen LM. Combined uridine and choline administration improves cognitive deficits in spontaneously hypertensive rats. Neurobiol Learn Mem 2003;80:63-79. (Pubitemid 36546208)
48. Holguin S, Martinez J, Chow C, Wurtman R. Dietary uridine enhances the improvement in learning and memory produced by administering DHA to gerbils. FASEB J 2008;22:3938-3946.
49. Holguin S, Huang Y, Liu J, Wurtman R. Chronic administration of DHA and UMP improves the impaired memory of environmentally impoverished rats. Behav Brain Res 2008;191:11-16.
50. Teather LA, Wurtman RJ. Chronic administration of UMP ameliorates the impairment of hippocampal-dependent memory in impoverished rats. J Nutr 2006;136:2834-2837. (Pubitemid 44771782)
51. De Wilde MC, Penke B, van der Beek EM, Kuipers AA, Kamphuis PJ, Broersen LM. Neuroprotective effects of a specific multi-nutrient intervention against Aβ42-induced toxicity in rats. J Alzheimers Dis 2011;27:327-339.
52. Broersen LM, Kuipers AA, Balvers M, van Wijk N, Savelkoul PJ, de Wilde MC, van der Beek EM, Sijben JW, Hageman RJ, Kamphuis PJ, Kiliaan AJ. A specific multi-nutrient diet reduces Alzheimer-like pathology in young adult AßPPswe/PS1dE9 mice. J Alzheimers Dis 2013;33:177-190.
53. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, Vcdin I, Vessby B, Wahiund LO, Palmblad J. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006;63:1402-1408. (Pubitemid 44547551)
54. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR, Weiner M, Shinto L, Aisen PS. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304: 1903-1911.
55. Katan MB, Deslypere JP, van Birgelen AP, Penders M, Zegwaard M. Kinetics of the incorporation of dietary fatty acids into scrum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study. J Lipid Res 1997;38:2012-2022. (Pubitemid 27468010)
56. Spiers PA, Myers D, Hochanadel GS, Lieberman HR, Wurtman RJ. Citicoline improves verbal memory in aging. Arch Neurol 1996;53:441-448. (Pubitemid 26143644)
57. De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther 2003;25:178-193.
58. Zeisel SH, Da Costa KA, Franklin PD, Alexander EA, Lamont JT, Sheard NF, Beiser A. Choline, an essential nutrient for humans. EASEB J 1991;5:2093-2098. (Pubitemid 121000174)
59. Veenema K, Solis C, Li R, Wang W, Maletz CV, Abratte CM, Caudill MA. Adequate intake levels of choline are sufficient for preventing elevations in serum markers of liver dysfunction in Mexican American men but are not optimal for minimizing plasma total homocysteine increases after a methionine load. Am J Clin Nutr 2008;88:685-692.
60. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998;316:894-898.
61. Aisen PS, Egelko S, Andrews H, Diaz-Airastia R, Weiner M, DeCarli C, Jagust W, Miller JW, Green R, Bell K, Sano M. A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease. Am J Geriatr Psychiatry 2003;11:246-249. (Pubitemid 36254199)
62. Eussen SJ, de Groot LC, Clarke R, Schneede J, Ueland PM, Hoefnagels WH, van Staveren WA. Oral cyanocobalamin supplementation in older people with vitamin B12 deficiency: a dose-finding trial. Arch Intern Med 12005;65:1167-1172.
63. Levine M, Wang Y, Padayatty SJ, Morrow J. A new recommended dietary allowance of vitamin C for healthy young women. Proc Natl Acad Sci USA 2001;98:9842-9846. (Pubitemid 32769391)
64. Biesalski HK. Vitamin E requirements in parenteral nutrition. Gastroenterology 2009;137(5 Suppl):S92-104.
65. Xia Y, Hill KE, Li P, Xu J, Zhou D, Motley AK, Wang L, Byrne DW, Burk RF. Optimization of selenoprotein P and other plasma selenium biomarkers for the assessment of the selenium nutritional requirement: a placebo-controlled, double-blind study of selenomethionine supplementation in selenium-deficient Chinese subjects. Am J Clin Nutr 2010;92:525-531.
66. Hurst R, Armah CN, Dainty JR, Hart DJ, Teucher B, Goldson AJ, Broadley MR, Motley AK, Fairweather-Tait SJ. Establishing optimal selenium status: results of a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2010;91:923-931.
67. van Wijk N, Hageman R, Kamphuis P, Broersen L, Sijben J. Specific nutrients to increase availability of components involved in neuronal membrane synthesis. Alzheimer's Association International Conference (AAIC), Paris, July 2011; Alzheimers Dement 2011;7(4 Suppl):S665-666 (abstract P3-469).
68. Scheltens P, Twisk JW, Blesa R, Scarpini E, von Arnim CA, Bongers A, Harrison J, Swinkels SH, Stam CJ, de Waal H, Wurtman RJ, Wieggers RL, Vellas B, Kamphuis PJ. Efficacy of Souvenaid® in mild Alzheimer's disease: results from a randomized, controlled trial. J Alzheimers Dis 2012;31:225-236.
69. Shah R et al. Souvenaid® as an add-on intervention in patients with mild to moderate Alzheimer's disease using Alzheimer's disease medication: results from a randomized, controlled, double-blind study (S-Connect). 4th congress of Clinical Trials on Alzheimer's Disease (CTAD), San Diego, November 2011; J Nutr Health Aging 2011;15(Suppl 1):S30 (abstract P38).
70. Vellas B, Andrieu S, Sampaio C, Wilcock G; European Task Force group . Disease-modifying trials in Alzheimer's disease: a European task force consensus. Lancet Neurol 2007;6:56-62. (Pubitemid 44880273)
71. Bender NK, Kraynak MA, Chiquette E, Linn WD, Clark GM, Bussey HI. Effects of marine fish oils on the anticoagulation status of patients receiving chronic warfarin therapy. J Thromb Thrombolysis 1998;5:257-261. (Pubitemid 28241452)
72. Dehmer GJ, Popma JJ, van den Berg EK, Eichhorn EJ, Prewitt JB, Campbell WB, Jennings L, Willerson JT, Schmitz JM. Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids. N Engl J Med 1988;319:733-740.
73. Harris WS. Expert opinion: omega-3 fatty acids and bleeding - cause for concern? Am J Cardiol 2007;99:44C-46C.
74. Leaf A, Jorgensen MB, Jacobs AK, Cote G, Schoenfeld DA, Scheer J, Weiner BH, Slack JD, Kellett MA, Raizner AE, et al. Do fish oils prevent restenosis after coronary angioplasty? Circulation 1994;90:2248-2257. (Pubitemid 24354309)
75. Gilman S, Roller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM; AN1792(QS-21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-1562. (Pubitemid 40617691)
76. Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol 2007;64:1323-1329. (Pubitemid 47403089)
77. Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, Gilman S, Arnold D, Abushakra S, Hernandez C, Crans G, Liang E, Quinn G, Bairu M, Pastrak A, Cedarbaum JM; ELND005-AD201 Investigators . Neurology 2011;77:1253-1262.
78. Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75:677-685. (Pubitemid 38526674)
79. Kamphuis PJ, Verhey FR, Olde Rikkert MG, Twisk JW, Swinkels SH, Scheltens P. Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer's disease: secondary analyses from a randomized, controlled trial. J Nutr Health Aging 2011;15:672-676.
80. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stem Y, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6:734-746. (Pubitemid 47058377)
81. Silva P, Kergoat MJ, Shatenstein B. Challenges in managing the diet of older adults with early-stage Alzheimer dementia: a caregiver perspective. J Nutr Health Aging 2013;17:142-147.
82. Richardson TJ, Lee SJ, Berg-Weger M, Grossberg GT. Caregiver health: health of caregivers of Alzheimer's and other dementia patients. Curr Psychiatry Rep 2013;15:367.